300702 天宇股份
已收盘 11-03 15:00:00
资讯
新帖
简况
天宇股份(300702.SZ)拟500万元参投武汉市佰诺嘉泰创业投资合伙企业
智通财经 · 19:38
天宇股份(300702.SZ)拟500万元参投武汉市佰诺嘉泰创业投资合伙企业
天宇股份（300702）2026年三季报简析：增收不增利
证券之星 · 10-31
天宇股份（300702）2026年三季报简析：增收不增利
天宇股份(300702)9月30日股东户数1.37万户，较上期减少2.34%
证券之星 · 10-30
天宇股份(300702)9月30日股东户数1.37万户，较上期减少2.34%
图解天宇股份三季报：第三季度单季净利润同比下降38.96%
证券之星 · 10-30
图解天宇股份三季报：第三季度单季净利润同比下降38.96%
股市必读：天宇股份新发布《关于全资子公司药品获得批准的公告》
证券之星 · 10-26
股市必读：天宇股份新发布《关于全资子公司药品获得批准的公告》
股市必读：天宇股份新发布《关于控股股东部分股份质押、展期及解除质押的公告》
证券之星 · 10-23
股市必读：天宇股份新发布《关于控股股东部分股份质押、展期及解除质押的公告》
天宇股份最新公告：全资子公司富马酸伏诺拉生片获药品注册证书
证券之星 · 10-22
天宇股份最新公告：全资子公司富马酸伏诺拉生片获药品注册证书
天宇股份（300702）10月21日主力资金净卖出531.03万元
证券之星 · 10-21
天宇股份（300702）10月21日主力资金净卖出531.03万元
天宇股份：公司正持续推进多肽、ADC等原料药新业务及酶工程平台建设
证券之星 · 10-20
天宇股份：公司正持续推进多肽、ADC等原料药新业务及酶工程平台建设
股市必读：天宇股份新发布《浙江天册律师事务所关于浙江天宇药业股份有限公司2026年第三次临时股东会的法律意见书》
证券之星 · 10-20
股市必读：天宇股份新发布《浙江天册律师事务所关于浙江天宇药业股份有限公司2026年第三次临时股东会的法律意见书》
天宇股份（300702）披露2026年员工持股计划获股东大会通过，10月19日股价下跌0.81%
证券之星 · 10-19
天宇股份（300702）披露2026年员工持股计划获股东大会通过，10月19日股价下跌0.81%
股市必读：天宇股份新发布《关于全资子公司药品获得批准的公告》
证券之星 · 10-16
股市必读：天宇股份新发布《关于全资子公司药品获得批准的公告》
天宇股份最新公告：全资子公司氢溴酸替格列汀片获药品注册批准
证券之星 · 10-15
天宇股份最新公告：全资子公司氢溴酸替格列汀片获药品注册批准
天宇股份：公司本次股份回购计划已实施完成
证券之星 · 10-14
天宇股份：公司本次股份回购计划已实施完成
天宇股份：现有高纯乙腈产能23,600吨
证券之星 · 10-14
天宇股份：现有高纯乙腈产能23,600吨
天宇股份：公司存货以原料药业务相关存货为主
证券之星 · 10-13
天宇股份：公司存货以原料药业务相关存货为主
天宇股份（300702）披露回购公司股份进展暨回购完成的公告，10月12日股价上涨1.53%
证券之星 · 10-12
天宇股份（300702）披露回购公司股份进展暨回购完成的公告，10月12日股价上涨1.53%
股市必读：天宇股份新发布《第六届董事会第四次会议决议公告》
证券之星 · 10-08
股市必读：天宇股份新发布《第六届董事会第四次会议决议公告》
天宇股份（300702）9月30日主力资金净卖出1250.78万元
证券之星 · 09-30
天宇股份（300702）9月30日主力资金净卖出1250.78万元
天宇股份（300702）9月28日主力资金净买入519.59万元
证券之星 · 09-28
天宇股份（300702）9月28日主力资金净买入519.59万元
加载更多
公司概况
公司名称：
浙江天宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-09-19
主营业务：
浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是沙坦类抗高血压药物原料药及中间体、抗哮喘药物原料药及中间体、降血糖药物原料药及中间体、降血脂类原料药及中间体、抗凝血原料药及中间体、CDMO原料药及中间体业务。
发行价格：
22.41
{"stockData":{"symbol":"300702","market":"SZ","secType":"STK","nameCN":"天宇股份","latestPrice":20.49,"timestamp":1793689416000,"preClose":20.21,"halted":0,"volume":1635391,"delay":0,"changeRate":0.0139,"floatShares":211000000,"shares":348000000,"eps":0.1991,"marketStatus":"已收盘","change":0.28,"latestTime":"11-03 15:00:00","open":20.2,"high":20.66,"low":19.93,"amount":33348300,"amplitude":0.0361,"askPrice":20.49,"askSize":123,"bidPrice":20.47,"bidSize":21,"shortable":0,"etf":0,"ttmEps":0.1991,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793755800000},"marketStatusCode":5,"adr":0,"adjPreClose":20.21,"symbolType":"stock","openAndCloseTimeList":[[1793669400000,1793676600000],[1793682000000,1793689200000]],"highLimit":22.23,"lowLimit":18.19,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":347977159,"isCdr":false,"pbRate":1.95,"roa":"--","peRate":102.913109,"roe":"4.05%","epsLYR":0.41,"committee":0.104478,"marketValue":7130000000,"turnoverRate":0.0077,"status":0,"floatMarketCap":4326000000},"requestUrl":"/m/hq/s/300702","defaultTab":"news","newsList":[{"id":"2680728974","title":"天宇股份(300702.SZ)拟500万元参投武汉市佰诺嘉泰创业投资合伙企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2680728974","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680728974?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:38","pubTimestamp":1793705902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天宇股份(300702.SZ)发布公告，公司与上海佰诺私募基金管理有限公司(以下简称“佰诺资本”)及其他有限合伙人签署了《武汉市佰诺嘉泰创业投资合伙企业(有限合伙)合伙协议》，公司作为有限合伙人，以自有资金500万元认缴武汉市佰诺嘉泰创业投资合伙企业(有限合伙)(以下简称“佰诺嘉泰”)部分份额，占佰诺嘉泰认缴出资总额的14.6199%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679222901","title":"天宇股份（300702）2026年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2679222901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679222901?lang=zh_cn&edition=full","pubTime":"2026-10-31 11:53","pubTimestamp":1793418837,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期天宇股份发布2026年三季报。根据财报显示，天宇股份增收不增利。截至本报告期末，公司营业总收入30.17亿元，同比上升15.44%，归母净利润1.5亿元，同比下降34.39%。持有天宇股份最多的基金为湘财医药健康混合A，目前规模为0.76亿元，最新净值1.6626，较上一交易日上涨0.01%，近一年上涨0.4%。本文数据来源于天宇股份2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100025616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679213074","title":"天宇股份(300702)9月30日股东户数1.37万户，较上期减少2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679213074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679213074?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:27","pubTimestamp":1793359660,"startTime":"0","endTime":"0","summary":"证券之星消息，近日天宇股份披露，截至2026年9月30日公司股东户数为1.37万户，较6月30日减少330.0户，减幅为2.34%。在化学制药行业个股中，天宇股份股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.98万户。从股价来看，2026年6月30日至2026年9月30日，天宇股份区间涨幅为12.5%，在此期间股东户数减少330.0户，减幅为2.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000047899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679239019","title":"图解天宇股份三季报：第三季度单季净利润同比下降38.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679239019","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679239019?lang=zh_cn&edition=full","pubTime":"2026-10-30 04:32","pubTimestamp":1793305934,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份2026年三季报显示，前三季度公司主营收入30.17亿元，同比上升15.44%；归母净利润1.5亿元，同比下降34.39%；扣非净利润1.45亿元，同比下降30.8%；其中2026年第三季度，公司单季度主营收入10.06亿元，同比上升20.12%；单季度归母净利润4657.53万元，同比下降38.96%；单季度扣非净利润4357.37万元，同比下降36.68%；负债率46.38%，投资收益260.37万元，财务费用6112.14万元，毛利率31.33%。财报数据概要请见下图:本文数据来源于天宇股份2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000006166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678131851","title":"股市必读：天宇股份新发布《关于全资子公司药品获得批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678131851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678131851?lang=zh_cn&edition=full","pubTime":"2026-10-26 05:53","pubTimestamp":1792965189,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，天宇股份报收于20.08元，上涨1.52%，换手率1.42%，成交量3.0万手，成交额5911.35万元。公司公告汇总关于全资子公司药品获得批准的公告浙江天宇药业股份有限公司全资子公司浙江诺得药业有限公司收到国家药监局核准签发的富马酸伏诺拉生片《药品注册证书》。公司对该品种累计研发投入约575.17万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600001477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677993756","title":"股市必读：天宇股份新发布《关于控股股东部分股份质押、展期及解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677993756","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677993756?lang=zh_cn&edition=full","pubTime":"2026-10-23 03:01","pubTimestamp":1792695672,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司诺得药业获富马酸伏诺拉生片《药品注册证书》，该药2025年国内销售额约10.67亿元。公司公告汇总关于控股股东部分股份质押、展期及解除质押的公告控股股东林洁女士持有公司股份122,028,474股，占公司总股本的35.07%；新质押650万股，展期920万股，解除质押230万股；截至公告日，累计质押2,920万股，占其持股总数的23.93%，占公司总股本的8.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300002546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677951213","title":"天宇股份最新公告：全资子公司富马酸伏诺拉生片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2677951213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677951213?lang=zh_cn&edition=full","pubTime":"2026-10-22 18:30","pubTimestamp":1792665020,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称，公司全资子公司浙江诺得药业近日收到国家药监局核准签发的富马酸伏诺拉生片《药品注册证书》。该药品用于反流性食管炎及根除幽门螺杆菌，2025年国内样本医院和实体药店销售额约10.67亿元。此次获批将进一步丰富公司制剂品种，有望增加制剂业务收入，提升市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200032215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677662592","title":"天宇股份（300702）10月21日主力资金净卖出531.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677662592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677662592?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:33","pubTimestamp":1792567981,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月21日收盘，天宇股份报收于20.13元，下跌3.41%，换手率1.26%，成交量2.66万手，成交额5463.57万元。10月21日的资金流向数据方面，主力资金净流出531.03万元，占总成交额9.72%，游资资金净流入123.58万元，占总成交额2.26%，散户资金净流入407.45万元，占总成交额7.46%。天宇股份主营业务：中间体、原料药以及制剂业务的研发、生产与销售。该股最近90天内共有2家机构给出评级，买入评级2家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100021522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676666940","title":"天宇股份：公司正持续推进多肽、ADC等原料药新业务及酶工程平台建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2676666940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676666940?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:03","pubTimestamp":1792486986,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份10月20日在投资者关系平台上答复投资者关心的问题。投资者提问：公司半年报提到在研仿制药原料药项目36个，其中多肽、ADC等新业务项目6个；酶工程平台完成1,000+酶库建设并实现2个产品酶工艺优化。公司正持续推进多肽、ADC等原料药新业务及酶工程平台建设。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000025448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676633546","title":"股市必读：天宇股份新发布《浙江天册律师事务所关于浙江天宇药业股份有限公司2026年第三次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676633546","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676633546?lang=zh_cn&edition=full","pubTime":"2026-10-20 02:31","pubTimestamp":1792434668,"startTime":"0","endTime":"0","summary":"公司公告汇总浙江天册律师事务所关于浙江天宇药业股份有限公司2026年第三次临时股东会的法律意见书浙江天册律师事务所就天宇股份2026年第三次临时股东会出具法律意见书。浙江天册律师事务所出具法律意见书，确认会议召集、召开程序及表决结果符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000002184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676684003","title":"天宇股份（300702）披露2026年员工持股计划获股东大会通过，10月19日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676684003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676684003?lang=zh_cn&edition=full","pubTime":"2026-10-19 22:48","pubTimestamp":1792421295,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘，天宇股份报收于20.72元，较前一交易日下跌0.81%，最新总市值为72.1亿元。该股当日开盘21.02元，最高21.13元，最低20.1元，成交额达4989.73万元，换手率为1.15%。近日，天宇股份发布《2026年第三次临时股东会决议公告》显示，公司于2026年10月19日召开2026年第三次临时股东会，会议采用现场与网络投票相结合方式，出席会议股东及授权代表共151名，代表股份占公司有表决权总股本的63.4406%。各项议案均获通过，表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900030586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675532367","title":"股市必读：天宇股份新发布《关于全资子公司药品获得批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675532367","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675532367?lang=zh_cn&edition=full","pubTime":"2026-10-16 02:46","pubTimestamp":1792089971,"startTime":"0","endTime":"0","summary":"公司公告汇总关于全资子公司药品获得批准的公告浙江天宇药业股份有限公司全资子公司浙江诺得药业有限公司近日收到国家药品监督管理局核准签发的氢溴酸替格列汀片《药品注册证书》，药品批准文号为国药准字H20266199，有效期至2031年10月12日。该药品适用于成人2型糖尿病患者的血糖控制。截至目前，国内另有三家生产企业获批该制剂。公司对该品种累计研发投入约597.42万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600002520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675921582","title":"天宇股份最新公告：全资子公司氢溴酸替格列汀片获药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675921582","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675921582?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:31","pubTimestamp":1792067473,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称，公司全资子公司浙江诺得药业近日收到国家药监局核准签发的氢溴酸替格列汀片《药品注册证书》。该药品用于改善成人2型糖尿病患者的血糖控制，注册分类为化学药品4类。据统计，2025年该药品在国内样本医院和城市实体药店销售额约0.796亿元。截至公告日，公司对该品种累计研发投入约597.42万元。此次获批将进一步丰富公司制剂品种，有望增加制剂业务收入，提升市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500036890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675342559","title":"天宇股份：公司本次股份回购计划已实施完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2675342559","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675342559?lang=zh_cn&edition=full","pubTime":"2026-10-14 20:48","pubTimestamp":1791982098,"startTime":"0","endTime":"0","summary":"投资者提问：公司已制定市值管理制度，截至7月底已回购约400万股、金额8,257万元，回购价格上限30.18元/股。公司本次股份回购计划已实施完成。根据回购方案，回购股份拟用于员工持股计划或股权激励。公司已于2026年9月30日披露《2026年员工持股计划（草案）》等相关公告，拟以回购股份作为该计划的股票来源。公司重视市值管理和股东回报，已制定《市值管理制度》。本次回购体现了公司对长期发展的信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400037551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675439666","title":"天宇股份：现有高纯乙腈产能23,600吨","url":"https://stock-news.laohu8.com/highlight/detail?id=2675439666","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675439666?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:39","pubTimestamp":1791938347,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份(300702)10月13日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问公司乙腈产能有多少？天宇股份回复：尊敬的投资者，您好！公司现有高纯乙腈产能分布在昌邑天宇和上海星可两个生产基地，其中昌邑天宇乙腈年产能20,000吨，上海星可乙腈年产能3,600吨。昌邑天宇2026年新增年产1万吨合成乙腈项目正在推进中，该项目旨在提升上游原料供应保障能力、加强产业链协同，项目具体进展请关注公司后续公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675820313","title":"天宇股份：公司存货以原料药业务相关存货为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2675820313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675820313?lang=zh_cn&edition=full","pubTime":"2026-10-13 11:36","pubTimestamp":1791862564,"startTime":"0","endTime":"0","summary":"截至2026年6月末，公司存货账面价值约15.42亿元，较年初减少1.88亿元，存货跌价准备余额约1.53亿元。公司存货以原料药业务相关存货为主，库存结构与业务布局及生产经营需求相匹配。公司将持续跟踪相关变化，并在各报告期末按照会计准则评估存货可变现净值，审慎计提存货跌价准备。公司将根据订单及市场需求统筹采购和生产，加强产销衔接，优化库存结构，提升存货周转效率，持续做好库存及减值风险管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300016313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674805733","title":"天宇股份（300702）披露回购公司股份进展暨回购完成的公告，10月12日股价上涨1.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674805733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674805733?lang=zh_cn&edition=full","pubTime":"2026-10-12 22:53","pubTimestamp":1791816803,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘，天宇股份报收于22.52元，较前一交易日上涨1.53%，最新总市值为78.36亿元。公司于2026年10月12日披露《关于回购公司股份的进展暨回购完成的公告》。公告显示，浙江天宇药业股份有限公司于2026年6月10日召开董事会，审议通过回购公司股份方案，拟使用自有资金以集中竞价方式回购股份，用于员工持股计划或股权激励。截至2026年10月12日，公司累计回购股份4,001,250股，占公司总股本的1.15%，成交金额82,571,643.50元，回购方案已实施完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200035835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673439014","title":"股市必读：天宇股份新发布《第六届董事会第四次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673439014","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673439014?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:21","pubTimestamp":1791393669,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第四次会议决议公告浙江天宇药业股份有限公司于2026年9月30日召开第六届董事会第四次会议，审议通过《2026年员工持股计划（草案）》及其摘要、《2026年员工持股计划管理办法》及提请股东大会授权董事会办理员工持股计划相关事项的议案，并决定召开2026年第三次临时股东大会。会议表决结果均为全票通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671895279","title":"天宇股份（300702）9月30日主力资金净卖出1250.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671895279","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671895279?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:28","pubTimestamp":1790753333,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，天宇股份报收于22.68元，上涨3.0%，换手率2.57%，成交量5.42万手，成交额1.23亿元。9月30日的资金流向数据方面，主力资金净流出1250.78万元，占总成交额10.2%，游资资金净流入466.82万元，占总成交额3.81%，散户资金净流入783.96万元，占总成交额6.4%。天宇股份主营业务：中间体、原料药以及制剂业务的研发、生产与销售。该股最近90天内共有2家机构给出评级，买入评级2家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000019049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670823542","title":"天宇股份（300702）9月28日主力资金净买入519.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670823542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670823542?lang=zh_cn&edition=full","pubTime":"2026-09-28 15:28","pubTimestamp":1790580519,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，天宇股份报收于22.25元，上涨4.46%，换手率1.66%，成交量3.5万手，成交额7601.23万元。9月28日的资金流向数据方面，主力资金净流入519.59万元，占总成交额6.84%，游资资金净流出131.28万元，占总成交额1.73%，散户资金净流出388.3万元，占总成交额5.11%。天宇股份主营业务：中间体、原料药以及制剂业务的研发、生产与销售。该股最近90天内共有2家机构给出评级，买入评级2家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800014579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793718270267,"stockEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.1089},{"period":"3month","weight":-0.0648},{"period":"6month","weight":-0.0202},{"period":"1year","weight":-0.2272},{"period":"ytd","weight":-0.1414}],"compareEarnings":[{"period":"1week","weight":-0.0161},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0482},{"period":"6month","weight":-0.1255},{"period":"1year","weight":-0.0801},{"period":"ytd","weight":-0.0834}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江天宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13746人(较上一季度减少2.34%)","perCapita":"15360股","listingDate":"2017-09-19","address":"浙江省台州市黄岩区黄岩江口化工开发区","registeredCapital":"34797万元","survey":" 浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是沙坦类抗高血压药物原料药及中间体、抗哮喘药物原料药及中间体、降血糖药物原料药及中间体、降血脂类原料药及中间体、抗凝血原料药及中间体、CDMO原料药及中间体业务。","listedPrice":22.41},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天宇股份,300702,天宇股份股票,天宇股份股票老虎,天宇股份股票老虎国际,天宇股份行情,天宇股份股票行情,天宇股份股价,天宇股份股市,天宇股份股票价格,天宇股份股票交易,天宇股份股票购买,天宇股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}